Efficacy of Splenectomy in Treating Refractory Autoimmune Hemolytic Anemia Linked to Systemic Lupus Erythematosus: A Case Study with Mechanistic Analysis - Report - MDSpire
Advertisement
Efficacy of Splenectomy in Treating Refractory Autoimmune Hemolytic Anemia Linked to Systemic Lupus Erythematosus: A Case Study with Mechanistic Analysis
Clinical Report: Efficacy of Splenectomy in Refractory AIHA Linked to SLE
Overview
This case study highlights the successful use of splenectomy in a patient with refractory autoimmune hemolytic anemia (AIHA) associated with systemic lupus erythematosus (SLE) after multiple failed therapies. The findings suggest that splenectomy may be a viable treatment option for select patients with refractory SLE-associated AIHA.
Background
Autoimmune hemolytic anemia (AIHA) is a serious complication of systemic lupus erythematosus (SLE), affecting approximately 5%–10% of SLE patients. Traditional treatments often fail, necessitating alternative options such as splenectomy, which has been considered a third-line treatment. Understanding the role of splenectomy in this context is crucial for optimizing management strategies for refractory cases.
Data Highlights
Parameter
Value
Reference Range
White blood cell count
2.74 × 10^9/L
3.5-9.5 × 10^9/L
Hemoglobin
41 g/L
115–150 g/L
Absolute reticulocyte count
228.7 × 10^9/L
25.7-75.0 × 10^9/L
Lactate dehydrogenase (LDH)
681 U/L
140–271 U/L
Total bilirubin
49.5 μmol/L
5-21 μmol/L
Direct antiglobulin test (DAT)
Positive (titer 1:16)
-
Key Findings
Splenectomy led to sustained hematologic improvement in a patient with refractory SLE-associated AIHA.
The patient had previously failed multiple treatments including glucocorticoids, rituximab, and therapeutic plasma exchange.
Splenic pathology indicated the spleen's role in erythrocyte destruction and abnormal immune responses.
IFI44L methylation findings supported the SLE-related immune background in this case.
Current guidelines recommend splenectomy as a consideration for refractory AIHA cases after other treatments fail.
Clinical Implications
Clinicians should consider splenectomy for patients with refractory SLE-associated AIHA who do not respond to conventional therapies. Careful patient selection and monitoring for potential complications, such as thromboembolism and infection, are essential.
Conclusion
This case underscores the potential role of splenectomy in managing refractory AIHA linked to SLE, warranting further investigation into its efficacy and safety in similar patient populations.
